Published in Cancer on July 15, 2002
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer (PR11) | NCT03624660
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol (2011) 2.57
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
Prostate cancer treatment. The case for radical prostatectomy. Ann R Coll Surg Engl (2006) 1.40
Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate (2012) 1.39
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol (2010) 1.12
Comparison of dose volume histograms for supine and prone position in patients irradiated for prostate cancer-A preliminary study. Rep Pract Oncol Radiother (2011) 1.06
Surgery vs. radiotherapy in localized prostate cancer. Which is best? Radiat Oncol (2008) 1.03
Basic principles of anatomy for optimal surgical treatment of prostate cancer. World J Urol (2007) 1.01
Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database. Qual Life Res (2009) 0.98
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92
Is there an optimal management for localized prostate cancer? Clin Interv Aging (2010) 0.91
Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int (2011) 0.89
Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. Mol Cancer (2016) 0.89
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol (2004) 0.85
Complications following robot-assisted radical prostatectomy in a prospective Canadian cohort of 305 consecutive cases. Can Urol Assoc J (2012) 0.85
SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines. Front Oncol (2014) 0.84
Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients. World J Urol (2014) 0.84
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs (2010) 0.83
MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples. Biomed Res Int (2014) 0.83
Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World J Urol (2008) 0.83
Shared decision-making--results from an interdisciplinary consulting service for prostate cancer. World J Urol (2004) 0.82
Variability in bladder volumes of full bladders in definitive radiotherapy for cases of localized prostate cancer. Strahlenther Onkol (2010) 0.81
Evaluation of prediction models for the staging of prostate cancer. BMC Med Inform Decis Mak (2013) 0.81
High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol (2013) 0.81
Role of radical prostatectomy for high-risk prostate cancer. Korean J Urol (2010) 0.81
Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. Radiat Oncol (2012) 0.80
Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes. Patient Relat Outcome Meas (2015) 0.78
Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit? Diagn Interv Radiol (2015) 0.78
Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer? Yonsei Med J (2015) 0.78
Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. BMC Urol (2015) 0.78
Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. World J Urol (2014) 0.78
Prostate cancer-specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy. Can Urol Assoc J (2013) 0.78
Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy. Korean J Urol (2015) 0.77
Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Front Oncol (2013) 0.77
High-grade prostate cancer: favorable results in the modern era regardless of initial treatment. ISRN Oncol (2012) 0.77
Novel anatomical identification of nerve-sparing radical prostatectomy: fascial-sparing radical prostatectomy. Prostate Int (2014) 0.77
The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. Prostate (2016) 0.75
Radical prostatectomy or external beam radiotherapy: one step forward or two steps back? Cancer (2002) 0.75
Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence? Int Braz J Urol (2015) 0.75
Preliminary safety and efficacy results with robotic high-intensity focused ultrasound : A single center Indian experience. Indian J Urol (2011) 0.75
Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy. BMC Urol (2015) 0.75
Contemporary update of cancer control after radical prostatectomy in the UK. Br J Cancer (2004) 0.75
First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. Prostate Cancer (2010) 0.75
Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy. Turk J Urol (2015) 0.75
Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma. Radiat Oncol J (2016) 0.75
Metachronous anal canal and prostate cancers with simultaneous definitive therapy: a case report and review of the literature. Case Rep Oncol Med (2011) 0.75
Properties and Implementation of Jeffreys's Prior in Binomial Regression Models. J Am Stat Assoc (2008) 0.75
Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares. Cancer (2002) 0.75
Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes. Radiat Oncol (2015) 0.75
PREDICT: model for prediction of survival in localized prostate cancer. World J Urol (2015) 0.75
Image-based monitoring of targeted biopsy-proven prostate cancer on active surveillance: 11-year experience. World J Urol (2015) 0.75
Does intensity-modulated radiation therapy (IMRT) alter prostate size? Magnetic resonance imaging evaluation of patients undergoing IMRT alone. Rep Pract Oncol Radiother (2017) 0.75
Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review. Curr Urol Rep (2017) 0.75
Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy. Virchows Arch (2014) 0.75
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 22.80
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 9.92
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Improving marginal likelihood estimation for Bayesian phylogenetic model selection. Syst Biol (2010) 4.32
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol (2002) 4.31
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest (2004) 3.90
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol (2003) 3.21
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res (2006) 3.04
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 2.85
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology (2006) 2.59
Computerized image-based detection and grading of lymphocytic infiltration in HER2+ breast cancer histopathology. IEEE Trans Biomed Eng (2009) 2.56
Expectation-maximization-driven geodesic active contour with overlap resolution (EMaGACOR): application to lymphocyte segmentation on breast cancer histopathology. IEEE Trans Biomed Eng (2010) 2.52
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy. Photochem Photobiol (2005) 2.33
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology (2007) 2.09
A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology (2009) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Missing data in clinical studies: issues and methods. J Clin Oncol (2012) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
High-throughput detection of prostate cancer in histological sections using probabilistic pairwise Markov models. Med Image Anal (2010) 2.04
Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size? Urology (2012) 2.03
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol (2002) 2.01
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med (2015) 2.01
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol (2010) 1.99
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol (2005) 1.98
Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum Pathol (2008) 1.89
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
The burden of depression in prostate cancer. Psychooncology (2011) 1.79
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol (2008) 1.72
Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology (2011) 1.70
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer (2007) 1.70
Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol (2007) 1.69
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer (2008) 1.66
Choosing among partition models in Bayesian phylogenetics. Mol Biol Evol (2010) 1.66
Management of the incidental renal mass. Radiology (2008) 1.66
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer (2008) 1.65
Bayesian analysis for generalized linear models with nonignorably missing covariates. Biometrics (2005) 1.65
Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol (2006) 1.64
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol (2008) 1.62
A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. Int J Radiat Oncol Biol Phys (2012) 1.61
PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 1.61
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol (2011) 1.58
Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol Urodyn (2010) 1.55
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys (2009) 1.55
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med (2007) 1.53
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol (2011) 1.52
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol (2011) 1.51
Racial differences in quality of life following prostate cancer diagnosis. Urology (2010) 1.51
Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys (2006) 1.50
Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer (2007) 1.50
Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant (2002) 1.49
Reducing or eliminating use of the category of atypical squamous cells of undetermined significance decreases the diagnostic accuracy of the Papanicolaou smear. Cancer (2002) 1.48
Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry (2011) 1.48
Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol (2002) 1.47
"Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts. Cancer (2005) 1.47